Clinician Position for SHC

Research and News March 2019

NSAIDs May Increase Risk for C. Difficile Infection
Protein & Fat Sources Matter on a Low-Carb Diet
Prebiotics Improve Bone Formation in Children with Celiac Disease
Update: Histamine Intolerance Symptoms
Sleep Disruption Creates Inflammation
Transforming 21st-Century Medicine – Clinical Ecology
Data Suggests Early-Life Antibiotic Exposure Tied to Celiac Risk
The Emergence of ‘Nutritional Psychiatry’

Episode 58: SPONSORED - Biocidin - Borrelia Research and Clinical Strategies using Botanical Antimicrobials

Episode 58: SPONSORED Biocidin – Borrelia Research and Clinical Strategies using Botanical Antimicrobials

Lyme disease (and co-infections) can be tough to treat. The Lyme spirochete, Borrelia burgdorferi, has adopted loads of devilishly clever cloaking devices – from thriving in biofilm to existing in pleomorphic forms – to ensure survival despite aggressive treatment. Enter botanical therapy. With or without concurrent antibiotics, botanical combinations are an essential component of the FxMed clinician’s toolkit.

Advances in Stool Testing: The GI-MAP™ GI-Microbial Assay Plus with Tony Hoffman

Episode 56: SPONSORED Advances in Stool Testing: The GI-MAP™ GI-Microbial Assay Plus with Tony Hoffman

I had loads of fun taking a tour through the wonderment of DSL GI MAP test today with Tony Hoffman, CEO of DSL (and longtime friend of mine!). DSL’s GI MAP stool test is, as CEO Tony Hoffman states, “a clinician diagnostic tool,” not a microbiome test. Yes, of course the GI MAP looks at the microbiome, but it’s not a broad sweep of the myriad bugs taking up residence.